@DamianReilly@JStonker I don't understand the bearish read on "not enough of those patients have experienced disease progression for us to be able to calculate that median PFS in this cohort." How can that be read bearishly?
... selling the Mag 7 names that ARE the AI trade. The trade eats itself. Both price for perfection, both fade below issue. The $8T in money funds won't save it: that cash does not rotate into trillion-dollar loss-makers on command (2/2)
The #SPCX and #Anthropic IPOs are a liquidity event wearing a growth story costume. ~$75B from SpaceX, Anthropic close behind, vs the ~$45B the ENTIRE US IPO market raised in all of 2025. That paper isn't bought with new money. It's funded by ... (1/2)
@NstaM0@Riccardino999 And conservative, as we would need to value 6k at a multiple of $1.5bn peak sales, it being the standard of care.. So even in your positive conservative view this is a great development
@royaldaring Agree. In other words, stay patient until EOY / beginning of 2027 for anything material to happen to #AVCT's SP (except for potential deal news on 6k)
@BenHarper121292@Blueberrymgmnt I fully agree Ben. There was quite some 'rambling' around the topic, and I believe expectations were being managed.
Also, I don't like the deal window analogy. That implies a window can close. In other words, no deal possible after July 26 according to this picture?
Unlikely
@tom_the_bomb__ Asking a question(s) to avoid confirmation bias
Was the enrollment question not always in the plan? Can we know?
Could it be that current 2 sites are just not recruiting enough patients so the's need to expand? Meaning P1 not progressing quick enough?